RT Journal Article
SR Electronic
T1 Longitudinal Analysis Reveals Distinct Antibody and Memory B Cell Responses in SARS-CoV2 Naïve and Recovered Individuals Following mRNA Vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.03.21252872
DO 10.1101/2021.03.03.21252872
A1 Goel, Rishi R.
A1 Apostolidis, Sokratis A.
A1 Painter, Mark M.
A1 Mathew, Divij
A1 Pattekar, Ajinkya
A1 Kuthuru, Oliva
A1 Gouma, Sigrid
A1 Kuri-Cervantes, Leticia
A1 Meng, Wenzhao
A1 Adamski, Sharon
A1 Baxter, Amy E.
A1 Giles, Josephine R.
A1 Weirick, Madison E.
A1 McAllister, Christopher M.
A1 Hicks, Amanda
A1 Korte, Scott
A1 Dougherty, Jeanette
A1 Long, Sherea
A1 D’Andrea, Kurt
A1 Hamilton, Jacob T.
A1 Luning Prak, Eline T
A1 Betts, Michael R.
A1 Bates, Paul
A1 Hensley, Scott E.
A1 Greenplate, Allison R.
A1 Wherry, E. John
YR 2021
UL http://medrxiv.org/content/early/2021/03/06/2021.03.03.21252872.abstract
AB Novel mRNA vaccines for SARS-CoV2 have been authorized for emergency use and are currently being administered to millions of individuals worldwide. Despite their efficacy in clinical trials, there is limited data on vaccine-induced immune responses in individuals with a prior SARS-CoV2 infection compared to SARS-CoV2 naïve subjects. Moreover, how mRNA vaccines impact the development of antibodies as well as memory B cells in COVID-19 experienced versus COVID-19 naïve subjects remains poorly understood. In this study, we evaluated antibody responses and antigen-specific memory B cell responses over time in 33 SARS-CoV2 naïve and 11 SARS-CoV2 recovered subjects. mRNA vaccination induced significant antibody and memory B cell responses against full-length SARS-CoV2 spike protein and the spike receptor binding domain (RBD). SARS-CoV2 naïve individuals benefitted from both doses of mRNA vaccine with additional increases in antibodies and memory B cells following booster immunization. In contrast, SARS-CoV2 recovered individuals had a significant immune response after the first dose with no increase in circulating antibodies or antigen-specific memory B cells after the second dose. Moreover, the magnitude of the memory B cell response induced by vaccination was lower in older individuals, revealing an age-dependence to mRNA vaccine-induced B cell memory. Side effects also tended to associate with post-boost antibody levels, but not with post-boost memory B cells, suggesting that side effect severity may be a surrogate of short-term antibody responses. The frequency of pre-vaccine antigen-specific memory B cells in SARS-CoV2 recovered individuals strongly correlated with post-vaccine antibody levels, supporting a key role for memory B cells in humoral recall responses to SARS-CoV2. This observation may have relevance for future booster vaccines and for responses to viral variants that partially escape pre-existing antibodies and require new humoral responses to be generated from memory B cells. Finally, post-boost antibody levels were not correlated with post-boost memory responses in SARS-CoV2 naïve individuals, indicating that short-term antibody levels and memory B cells are complementary immunological endpoints that should be examined in tandem when evaluating vaccine response. Together, our data provide evidence of both serological response and immunological memory following mRNA vaccination that is distinct based on prior SARS-CoV2 exposure. These findings may inform vaccine distribution in a resource-limited setting.Competing Interest StatementEJW is consulting or is an advisor for Merck, Elstar, Janssen, Related Sciences, Synthekine and Surface Oncology. EJW is a founder of Surface Oncology and Arsenal Biosciences. EJW is an inventor on a patent (US Patent number 10,370,446) submitted by Emory University that covers the use of PD-1 blockade to treat infections and cancer.Funding StatementThis work was supported by grants from NIH: AI105343 and AI082630 (EJW); T32 AR076951-01 (SAA); HL143613, and T32 CA009140 (JRG). This work was also supported by the University of Pennsylvania Perelman School of Medicine COVID fund; the Allen Institute for Immunology (SAA, EJW); the Chen Family Research Fund (SAA); and a Cancer Research Institute-Mark Foundation Fellowship (JRG). RRG was supported through a Raffensperger 21st Century Scholar Award from the University of Pennsylvania. JRG and EJW are also funded by the Parker Institute for Cancer Immunotherapy which supports the Cancer Immunology Program at the University of Pennsylvania. We further thank Jeffrey Lurie and Joel Embiid, Josh Harris, and David Blitzer for philanthropic support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:44 individuals (33 SARS-CoV2 naive, 11 SARS-CoV2 recovered) were consented and enrolled in the study with approval from the University of Pennsylvania Institutional Review Board (IRB# 844642).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available from the authors upon request.